Croda Pharma wins ‘Best Production/Process Development’ Award at the 17th annual Vaccine Industry Excellence awards

PRESS RELEASE

08 April 2024: Croda Pharma has been awarded winner of a prestigious award for its process development for innovative ingredients, including its production of sustainably sourced Squalene to replace shark-derived squalene for the vaccine industry. 

The company was awarded the ‘Best Production/Process Development award’ at the 17th Annual ViE Awards 2024. The awards, which celebrate the industry’s most outstanding achievements and contributions to vaccines, recognised Croda Pharma for its process development for sustainably sourced and highly purified Squalene. A process which has unlocked a more sustainable alternative to shark-derived squalene, at the purity level required for vaccines.

This comes closely after Croda announced a key partnership with Amyris, a leading synthetic biotechnology company, to develop and supply sustainably sourced Squalene for vaccines, addressing a key industry challenge in the journey to more sustainable vaccines. 

Laura Ciccardi, Global Business Development Manager, accepted the award on behalf of Croda, alongside Dr. Dennis Christensen, Head of Global Research and Development – Adjuvant Systems and Dr. Rasmus Münter, Lead Research Scientist – Adjuvant Systems. 

Commenting, Laura Ciccardi said: “It is a great recognition of all our efforts to make sustainable and innovative adjuvant systems available to the world. I am very proud we have received this award”.

Dennis Christensen also added: “We have unlocked a yeast-based, sustainably sourced Squalene of superior quality ≥99% pure, that carries the same benefits as shark-derived squalene. Our Squalene can be used in novel vaccine adjuvant systems applicable in many important vaccines against diseases such as seasonal and pandemic influenza, tuberculosis, shingles, schistosomiasis, HIV, and other vaccine preventable diseases.” 

Croda’s most recent partnerships include a new partnership with AAHI, The Access to Advanced Health Institute, to provide access to novel adjuvant systems. It has also collaborated with BSI, Botanical Solutions Inc, to add another cutting-edge technology to its portfolio, providing QS 21 from sustainable raw material sources and to secure consistent and reliable supply of saponins for lifesaving vaccines. Both partnerships underline Croda’s commitment to develop and market sustainable vaccine adjuvant components and systems.

The awards show, hosted alongside the World Vaccines Congress in Washington, USA, also recognised achievements from GSK, Pfizer and Moderna in other categories for the awards. 

About Amyris 
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company’s proprietary Lab-to-Market™ technology platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit www.amyris.com.